• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Walgreens shares down after soft earnings report

Article

Despite increases in earnings and net income, Walgreens shares dropped this week after the company’s third-quarter earnings fell short of Wall Street expectations.

Despite increases in earnings and net income, Walgreens shares dropped this week after the company’s third-quarter earnings fell short of Wall Street expectations.

The company’s adjusted earnings for the quarter increased 29.3% to $812 million, or 85 cents a share. That was 6 cents less than what analysts forecast.

Meanwhile, net income for the quarter jumped 16.2% to $624 million, or 65 cents a share.  Walgreens net income for the same period last year was $537 million, or 62 cents a share. On Tuesday, Walgreens stock dropped nearly 6% and closed at  $45.22. 

“Our front-end sales are still not up to our expectations, and while the economy remains challenging, increasing customer traffic and front-end sales are our near-term priorities with a focus on pricing and promotion and the leveraging of our Balance Rewards program, which now has 75 million members,” said Greg Wasson, Walgreen’s CEO.

Walgreens’ third quarter sales rose 3.2% to $18.3 billion, which included an 8.7% increase in prescription volume. However, the company reported that customer traffic in stores decreased by 3.9%.

 

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.